Karen Affleck
- Oncology top 5%
- Molecular Biology
- Pulmonary and Respiratory Medicine top 10%
- Radiology, Nuclear Medicine and Imaging top 10%
- Physiology
- Co-authors
- Doris M. MurrayBarry R. KeithEdgar R. WoodWilson B. KnightKaren LackeyDavid W. RusnakTona M. GilmerRobert J. Mullin
- Topics
- HER2/EGFR in Cancer Research (6 papers)Mast cells and histamine (5 papers)Asthma and respiratory diseases (5 papers)
- Journals
- Journal of Biological ChemistryThe Journal of PhysiologyInternational Journal of Molecular Sciences
- Partner nations
- United KingdomUnited StatesNetherlands
In The Last Decade
Karen Affleck
24 papers receiving 1.2k citations
Hit Papers
Peers
Comparison fields: 5 of 83
- Oncology 567
- Molecular Biology 489
- Pulmonary and Respiratory Medicine 316
- Radiology, Nuclear Medicine and Imaging 203
- Physiology 141
Countries citing papers authored by Karen Affleck
This map shows the geographic impact of Karen Affleck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Affleck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Affleck more than expected).
Fields of papers citing papers by Karen Affleck
This network shows the impact of papers produced by Karen Affleck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Affleck. The network helps show where Karen Affleck may publish in the future.
Co-authorship network of co-authors of Karen Affleck
This figure shows the co-authorship network connecting the top 25 collaborators of Karen Affleck. A scholar is included among the top collaborators of Karen Affleck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Affleck. Karen Affleck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 2 | |
| 3 | 20 | |
| 4 | 8 | |
| 5 | 25 | |
| 6 | 27 | |
| 7 | 24 | |
| 8 | 2 | |
| 9 | 18 | |
| 10 | 23 | |
| 11 | 36 | |
| 12 | 16 | |
| 13 | 109 | |
| 14 | 40 | |
| 15 | 63 | |
| 16 | The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.breakdown → | 590 |
| 17 | 11 | |
| 18 | 16 | |
| 19 | 8 | |
| 20 | 47 |
About Karen Affleck
Karen Affleck is a scholar working on Equine, Biological Psychiatry and Immunology, having authored 24 papers that have together received 1.2k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (6 papers), Mast cells and histamine (5 papers) and Asthma and respiratory diseases (5 papers). The work is most often cited by research in Equine (61 citations), Oncology (567 citations) and Genetics (127 citations). Karen Affleck has collaborated with scholars based in United Kingdom, United States and Netherlands. Frequent co-authors include Doris M. Murray, Barry R. Keith, Edgar R. Wood, Wilson B. Knight, Karen Lackey, David W. Rusnak, Tona M. Gilmer, Robert J. Mullin, Nelson Rhodes and Krystal J. Alligood. Their work appears in journals such as Journal of Biological Chemistry, The Journal of Physiology and International Journal of Molecular Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.